Details of the Use of Non-steroidal Anti-inflammatory Drugs in Comorbid Patients. Ways to Minimise the Risks of NSAID-induced GIT Complications

Objective of the Review: to discuss the most common adverse events from the use of non-steroidal anti-inflammatory drugs (NSAID) for GIT: NSAID-induced esophago-, gastroduodeno- and enteropathy, possible management and the use of various therapies in order to minimize the risks of this pathology. Key Points. NSAIDs are efficient analgetics and anti-inflammatory products widely used in clinical setting. NSAIDs are prescribed mostly to patients with chronic joint and spine conditions. As a lot of patients who take NSAIDs are comorbid, they have frequent adverse reactions to drugs, including NSAIDs, and need stricter control if this is a therapy of choice. Selective NSAIDs (nimesulide) are characterised by good bioavailability; they are efficient pain killers, possess marked anti-inflammatory properties and are relatively safe, thus making it possible to minimise the rate of adverse reactions for GIT. Conclusion. It should be emphasised that the issue of NSAID-induced GIT disorders is still challenging and can be aggravated in comorbid patients. Of prime importance are timely prevention and diagnosis of NSAID-induced GIT disorders and sustainable and individuated NSAID prescription. Keywords: non-steroidal anti-inflammatory drugs, comorbidity, NSAID-induced gastroduodenopathy, NSAID-induced enteropathy, nimesulide, Nise

Download Full-text

Faculty Opinions recommendation of Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.11531956.14741149 ◽

2011 ◽

Author(s):

Michael Schaefer ◽

Erika Schulte

Keyword(s):

Adverse Events ◽

Crossover Study ◽

Case Crossover ◽

Inflammatory Drugs ◽

Anti Inflammatory ◽

Gastrointestinal Adverse Events ◽

Upper Gastrointestinal

Download Full-text

Adverse reactions with the use of non-steroidal anti-inflammatory drugs

Vrač skoroj pomoŝi (Emergency Doctor) ◽

10.33920/med-02-2008-02 ◽

2020 ◽

pp. 35-50

Author(s):

M. L. Maksimov ◽

N. M. Kiseleva ◽

D. G. Semenikhin ◽

B. K. Romanov

Keyword(s):

Risk Factors ◽

Adverse Reactions ◽

Effective Prevention ◽

Chemical Structures ◽

Wide Range ◽

Inflammatory Drugs ◽

Anti Inflammatory ◽

Prevention Method ◽

Effective Medication ◽

Upper Gastrointestinal

Non-steroidal anti-inflammatory drugs (NSAIDs) are included in a pharmacological group of drugs with different chemical structures providing anti-inflammatory, analgesic and antipyretic actions, as well as antiplatelet action to a certain degree. Unfortunately, NSAIDs can cause a wide range of adverse reactions (AR) posing a serious risk to the health and life of patients. Therefore, the rational use of NSAIDs should include methods for effective prevention of drug complications. Many NSAIDs have a pronounced therapeutic effect, simultaneously causing many undesirable effects, so the drug shall be chosen considering the development of predicted side effects and modern algorithms. According to clinical recommendations, risk factors and administration of safer NSAIDs shall be considered as the main prevention method. Besides, it is possible to protect the patient from the upper gastrointestinal tract complications using proton pump inhibitors. It should be noted that there are no effective medication methods for kidney and liver protection to reduce the risk of NSAID-associated complications.

Download Full-text

Risedronate Did Not Increase Gastrointestinal Adverse Events(AES) In Subjects Taking Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) Or Aspirin

Journal of Clinical Densitometry ◽

10.1016/j.jocd.2008.05.071 ◽

2008 ◽

Vol 11 (3) ◽

pp. 464

Author(s):

Robert Lindsay ◽

Jay L. Goldstein ◽

Xiaojie Zhou ◽

Christian Roux ◽

Andreas Gruauer

Keyword(s):

Adverse Events ◽

Inflammatory Drugs ◽

Anti Inflammatory ◽

Gastrointestinal Adverse Events

Download Full-text

Efficacy and safety of non-steroidal anti-inflammatory drugs for acute attack of gout

Russian Medical Inquiry ◽

10.32364/2587-6821-2021-5-2-96-101 ◽

2021 ◽

Vol 5 (2) ◽

pp. 96-101

Author(s):

V.B. Vasilyuk ◽

◽

G.I. Syraeva ◽

M.V. Faraponova ◽

◽

...

Keyword(s):

Inflammatory Arthritis ◽

Adverse Reactions ◽

Acute Attack ◽

Therapeutic Modality ◽

Efficacy And Safety ◽

Nsaid Treatment ◽

Depth Analysis ◽

Inflammatory Drugs ◽

Anti Inflammatory ◽

Russian Medical

Gout is one of the most common forms of inflammatory arthritis. Medical care for gout includes non-steroidal anti-inflammatory drugs (NSAIDs). This paper reviews the efficacy and safety of NSAIDs prescribed for the acute attack of gout, in particular, AMBENIUM® parenteral. It was demonstrated that phenylbutazone is a powerful NSAID that provides significant analgesic and anti-inflammatory effects. Considering a broad spectrum of adverse reactions of NSAIDs, these agents should be prescribed and used under in-depth analysis of patient’s condition, comorbidities and the level of their decompensation, and potential drug interactions. In addition, optimal dosages and duration of NSAID treatment are of particular importance. The authors conclude that AMBENIUM® parenteral is an effective and safe therapeutic modality for gout. Its profile and risk/benefit ratio are regarded as “favorable” compared to other NSAIDs. KEYWORDS: gout, arthritis, pain, non-steroidal anti-inflammatory drugs, parenteral, efficacy, safety. FOR CITATION: Vasilyuk V.B., Syraeva G.I., Faraponova M.V. Efficacy and safety of non-steroidal anti-inflammatory drugs for acute attack of gout. Russian Medical Inquiry. 2021;5(2):96–101. DOI: 10.32364/2587-6821-2021-5-2-96-101.

Download Full-text

The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria

Journal of Health Economics and Outcomes Research ◽

10.36469/9865 ◽

2013 ◽

Vol 1 (2) ◽

pp. 184-199 ◽

Cited By ~ 1

Author(s):

Nadir Hammoumraoui ◽

Sid Ahmed Kherraf ◽

Joaquin Mould-Quevedo ◽

Tarek A. Ismail

Keyword(s):

Cost Effectiveness ◽

Adverse Events ◽

Proton Pump ◽

Cost Effective ◽

Private Clinic ◽

Effective Treatment Option ◽

Life Years ◽

Cost Effective Treatment ◽

Inflammatory Drugs ◽

Anti Inflammatory

Background: Cyclooxygenase-2 inhibitors such as celecoxib are as effective as non-selective non-steroidal anti-inflammatory drugs (ns-NSAIDs) in the treatment of osteoarthritis (OA), have fewer gastrointestinal side effects, but are more expensive. Objective: To evaluate the incremental cost-effectiveness ratio (ICER) of celecoxib versus ns-NSAIDs, with/without proton-pump inhibitor (PPI) co-therapy, for treating OA in Algeria. Methods: The National Institute for Health and Clinical Excellence (NICE) health economic model from UK, updated with relative risks of adverse events using CONDOR trial data, was adapted for costeffectiveness analysis in OA patients aged ≥65 years. Patients could initiate treatment with celecoxib or ns-NSAIDs with/without omeprazole. Conditional probabilities were obtained from published clinical trials; effectiveness measure was quality-adjusted life years (QALYs) gained/patient. The analysis was conducted from a healthcare payer’s perspective. The average daily treatment costs and frequencies of resource use for adverse events were based on data collected in August 2011 from a private clinic located in Cheraga, Algiers, Algeria. Probabilistic sensitivity analysis (PSA) was performed to construct cost-effectiveness acceptability curves (CEACs). Results: QALYs gained/patient over a 6-month horizon were higher with celecoxib (0.368) and celecoxib+PPI (0.40) versus comparators. The lowest expected cost/patient was associated with ibuprofen (US$134.76 versus US$175.67 with celecoxib+PPI, and US$177.57 with celecoxib). Celecoxib+PPI was the most cost-effective drug treatment, with an ICER of US$584.43, versus ibuprofen. Treatment with celecoxib alone showed an ICER of US$1,530.56 versus diclofenac+PPI. These ICERs are <1 gross domestic product per capita in Algeria (US$7,500). Over 1-year, 3-year and 5-year horizons, celecoxib with/without PPI co-therapy showed higher QALYs/patient versus comparators, and decreasing ICERs. The ICER of celecoxib+PPI was lower than that of comparators over all time horizons. These findings were confirmed with CEACs generated via PSA. Conclusion: Using data from a single private clinic in Cheraga, Algiers, Algeria, and after considering new adverse event risks, we showed that celecoxib with/without PPI co therapy is more cost-effective than ns-NSAID+PPI for treating OA patients aged ≥65 years. Celecoxib+PPI remains dominant over a 5-year horizon, making it the most cost-effective treatment option for medium- and long-term use.

Download Full-text

Acute Myopericarditis in a Pediatric Patient after First Dose of Pfizer BioNTech COVID - 19 Vaccination: First Case Report in the Kingdom of Bahrain

Journal of the Bahrain Medical Society ◽

10.26715/jbms.33_2021_4_7 ◽

2021 ◽

Vol 33 (4) ◽

pp. 29-32

Author(s):

Ghada Al Qassim ◽

Vimalarani Arulselvam ◽

Suad R Al Amer ◽

Salah Al Ghanem ◽

Neale Nicola Kalis

Keyword(s):

Case Report ◽

Adverse Events ◽

Pediatric Patient ◽

Task Force ◽

Limited Data ◽

First Case ◽

National Task ◽

Inflammatory Drugs ◽

Anti Inflammatory

Coronavirus disease 201 9 (COVID - 1 9 ) vaccination for children over 12 years of age began on May 2021 in the kingdom of Bahrain. Very limited data is available regarding the adverse events related to COVID -19 vaccination in children. This is a case report of a 12-year-old previously healthy boy with acute myopericarditis who presented on day 5 after the first dose of Pfizer COVID - 19 vaccination. Other causes of acute myopericarditis were ruled out. He was treated with non - steroidal anti-inflammatory drugs and recovered fully. This case of vaccine-induced myocarditis was reported to the national task force of Bahrain for combating COVID - 19.

Download Full-text